College Stock: Penny Stock News

Inovio Biomedical Corp. (AMEX: INO) is not The Dean’s next Ivy League Stock Pick but the company is focused on the development and discovery of DNA vaccines for the treatment and prevention of cancer and infectious diseases like HIV. The Dean has done his homework and has found some interesting similarities between $INO‘s DNA based therapies and $VRAL‘s protein based therapies.

$INO‘s treatments are DNA based. DNA, or deoxyribonucleic acid, is a nucleic acid that contains a set of genetic instructions which specify the sequence of amino acids with proteins. Since $VRAL‘s VGV-1 injectable drug consists of thymus nuclear protein (TNP) which was originally studied as a means of early detection for certain types of cancers, the way their technology works to fight infection and disease could be similar to $INO‘s.

TNP and other thymic proteins are thought to suppress the rate of infection in the HIV infected individuals and The  Dean believes $VRAL is determined to bring their VGV-1 into clinical trials and production and recent news from $INO could bring $VRAL even more potential in the long run.

$VRAL‘s therapies are considered immune-based because of their ability to help the body’s natural defense system do a better job of eliminating pathogens that carry infection or keep the infection thriving inside the human body. The most developed and FDA approved therapies which use this technology work by boosting the body’s immune system and training the body to fight off viral infections after treatment.

There are a number of these therapies being developed but none have been approved for use on individuals infected with HIV and AIDS. As a result, therapies have been combined to improve effectiveness but, as seen in the recent Thailand trials, results are not effective enough for approval.

The Dean believes there is hope for $VRAL and other companies working towards HIV/AIDS treatment and prevention because therapeutic and preventative vaccines are currently being used to protect individuals from polio, smallpox, Hepatitis A and B, mumps and the measles.

$INO has received media attention recently because their SynCon(TM) H1N1 vaccine has showed promising results in mice, pigs and ferrets. Such therapies have great potential because they used DNA and protein-based technology to improve the immune system in immunosuppressed (infected and deteriorating) individuals.

The Dean’s excited about $INO‘s success because their developments and immune-based therapies have been welcomed for consideration by giants like Merck (NYSE: MRK).

$VRAL‘s VGV-1 injectable drug is said to have demonstrated an antiviral effect in pilot studies but further studies are needed to determine their drug’s effect on the immune system and levels of HIV in the blood of infected individuals. The Dean knows these types of studies are extremely expensive but, at the same time, recent developments with the Recovery Act has awarded $5 billion for HIV/AIDS research, in an effort to create jobs while making further progress in the fight against this deadly viral disease.

Be sure to sign up for Honors Class to learn about The Dean’s Ivy League Stock Picks and other promotions before the rest of the CollegeStock Community.

Students have until October 10th to become eligible for The Dean’s first ever Scholarship Fund contest. To be eligible, you MUST be an Honors Student. With The Dean giving away $5,000 to one top-performing Honors Students every quarter, $9.87/month to register for Honors Class is the ONLY way to get to the head of the class.